Pregnancy-Related Issues in the Management of Addictions - PowerPoint PPT Presentation

1 / 57
About This Presentation
Title:

Pregnancy-Related Issues in the Management of Addictions

Description:

Pregnancy-Related Issues in the Management of Addictions Train the Trainer Workshop Problematic Substance Use in Pregnancy (PSUP) www.addictionpregnancy.ca – PowerPoint PPT presentation

Number of Views:74
Avg rating:3.0/5.0
Slides: 58
Provided by: addictionp
Category:

less

Transcript and Presenter's Notes

Title: Pregnancy-Related Issues in the Management of Addictions


1
Pregnancy-Related Issues in the Management of
Addictions
Train the Trainer Workshop Problematic Substance
Use in Pregnancy (PSUP) www.addictionpregnancy.ca
Last modified March 2008
2
Conflict of Interest Disclosure
  • Financial support for this workshop was provided
    by Health Canada
  • Funding for the PRIMA Pocket Reference was
    provided by the Lawson Foundation
  • No commercial sponsorship has been received to
    support this program

3
Pregnancy-Related Issues in the Management of
Addictions
  • Problematic Substance Use in Pregnancy
  • Community Presentation

4
Objectives
  • Define an approach to care for problematic
    substance use in pregnancy (PSUP)
  • screening and epidemiology
  • Describe prenatal care in the context of
    substance use treatment
  • Describe the effects of common substances
  • Describe care at delivery and postpartum
  • Describe resources available

5
Reasons Women Use Drugs
  • Cope with history of mental health problems /or
    sexual abuse
  • Cope with stressors of poverty and racism
  • Cope with problems/stress, e.g., violence, family
    separation
  • Cope with feelings of lack of self-worth or
    inadequacy
  • Influenced by substance use of partners
  • Control weight gain
  • Desire for recreation

6
High Risk Groups of Women
  • History of abuse (physical, sexual, emotional)
  • Low income status
  • Young age with little or no support
  • Unplanned unwanted pregnancy
  • Previous child with developmental delay
  • History of mood/anxiety disorder or eating
    disorder

7
Approach to Care - Principles
  • Woman-centered, nonjudgmental care is crucial
  • Establishing rapport is the single most important
    aspect of the initial encounter
  • Disclosure of use should be seen as positive
  • The antenatal period is often a time when women
    are ready to change
  • Address the womans needs and withdrawal symptoms
    before moving on
  • Try not to fix everything!!!

8
Approach to Care-Principles (2)
  • Prior relationships with health care providers
    have often been negative
  • There is a high percentage of survivors of sexual
    abuse among women with PSUP - sensitive
    interviewing is required (defer pelvic exam
    unless required)
  • Work to establish trust through communication
  • Ensure she is safe to leave - increased risk for
    intimate partner violence
  • Meet her needs as she identifies them (i.e.,
    food, shelter, etc.)
  • (contd)

9
Approach to Care-Principles (3)
  • Watch for nonverbal cues
  • Is she feeling vulnerable?
  • Is she in withdrawal?
  • Does she understand what you are saying?
  • Does she appear hungry?
  • Does she require clothing or shelter?
  • Does she have a mental health problem?
  • Remember that the appearance of belligerence or
    anger may signify fear, pain or withdrawal!

10
Identify Key Issues at First Visit
  • Explore whether she is in withdrawal
  • Enquire about acute and chronic medical
    conditions
  • Ask about medications OTC and herbal products
  • Ask if she is safe and has adequate nutrition
  • FIFE
  • What does she feel about her substance use?
  • What are her ideas about how she started using?
  • How is she functioning?
  • What are her expectations about provider
    involvement?
  • Plan for follow-up soon after initial encounter

It is better to do less than more at the first
visit so that she will come back!
11
Comprehensive Assessment
  • Screening by interviewing for substances used
  • Alcohol
  • Nicotine
  • Marijuana
  • Cocaine and other Stimulants
  • Opiates, illegal and prescribed
  • Benzodiazepines
  • Inhalants
  • Hallucinogens and Designer Drugs
  • (contd)

12
Screening Test T-ACE
  • T ToleranceHow many drinks does it take for
    you to feel the effects?
  • A AnnoyedHave people annoyed you by
    criticizing your drinking?
  • C Cut downHave you ever felt you should cut
    down on your drinking?
  • E Eye-openerHave you ever had a drink in the
    morning to steady your nerves or get going?

13
T-ACE Scoring
  • T 2 points if it takes 2 or more drinks
  • A,C,E 1 point each for yes
  • A total score of 2 points or more indicates the
    woman is likely to have a problem with alcohol

14
Screening Test TWEAK
  • T How many drinks before you feel high?
    (Tolerance record of drinks)
  • W Has anyone worried about your drinking in past
    year?
  • E Do you need a drink in the morning to get
    going? (Eye opener)
  • A Has anyone ever told you about things you said
    or did while you were drinking that you could not
    remember? (Amnesia or blackouts)
  • K (C) Have you felt the need to cut down?

15
TWEAK Scoring
  • T 2 points if it takes 3 or more drinks to feel
    the
  • effects of alcohol
  • W 2 points if yes
  • E, A, K 1 point each for yes
  • A total score of 3 or more points indicates that
    the woman is likely to have a drinking problem.

16
Comprehensive Assessment
  • This comprehensive history may be completed over
    several visits
  • Complete drug history name of drug, amount,
    frequency, duration, route(s), last use, needle
    sharing or injection drug use (IDU)
  • History of withdrawal symptoms
  • Consequences of drug use
  • Previous treatment programs, mutual aid groups
  • Medical history HIV, Hepatitis B C, STIs
  • Obstetrical history GxPy, LMP, cycle regularity
  • Social History partner, living children
  • (contd)

17
Comprehensive Assessment
  • Further issues to identify after the
    establishment of a therapeutic relationship
  • Psychiatric history eating disorders, mood
    disorders
  • Social history family situation (partner, of
    children), housing nutrition, legal (current
    charges court dates), finances, domestic
    violence child abuse (safety)
  • Family history substance use, psychiatric
    disorders, genetic and congenital disorders
  • Sexual abuse history very common among substance
    using women so use sensitive interviewing
    techniques

(contd)
18
Comprehensive Assessment
  • Consider screening for intimate partner violence
  • ALPHA (Antenatal Psychosocial Health Assessment)
  • Three key questions
  • Have you ever experienced abuse?
  • Are you or have you ever been afraid of your
    partner?
  • Are you safe?
  • ALPHA http//dfcm19.med.utoronto.ca/research/alph
    a

(contd)
19
Comprehensive Assessment
  • Child Protection Concerns
  • Remember - there is no legal obligation to report
    the unborn child
  • Not all women will require child protection
    services some will require support services
  • Be honest about your legal obligation to inform
    child protection services once the baby is born
  • Identify any risks to children that may be living
    with woman - will need to clarify disposition of
    all living children
  • Encourage voluntary self-reporting

20
Physical Examination
  • Unless clear medical emergency can defer detailed
    medical exam
  • Vital signs, fetal heart rate and mothers weight
    are key components at each encounter
  • Defer pelvic exam until rapport has been
    established (possible history of sexual abuse
    will require sensitivity during exam)
  • Obstetrical exam - FHR, Symphysis fundal height
  • Target exam to reflect / detect substance use
  • Skin for injection sites, cellulitis, cuts,
    bruises nasal passages
  • Cardiac exam murmur
  • Abdominal exam enlarged liver

21
Investigations
  • Bloodwork Quantitative Serum B-hcg, routine
    prenatal bloodwork, liver enzymes, HIV and
    Hepatitis C serology (with consent)
  • Urine routine and microscopy, culture and
    sensitivity
  • Ultrasound for dates (if uncertain) and
    morphology
  • Consider drug toxicology testing (with consent),
    as needed

22
Screening for Infections
  • Screen as required for
  • Hepatitis B with HbsAg and Antibody levels
  • Hepatitis C antibody testing
  • Syphilis
  • HIV (requires informed consent to perform test)
  • Mantoux (need to ascertain her previous status)
  • Chlamydia and gonorrhea
  • Retest as exposure dictates due to window periods
    for conversion

23
Hepatitis C (HCV) Infection
  • Rates of HCV infection up to 90 following more
    than 5 years injection drug use
  • Seroconversion occurs most frequently in the
    first year of injection use
  • Rate of vertical transmission 0 to 5
  • No treatment for HCV during pregnancy
  • Confirm if acute or chronic HCV infection
  • Consider Hepatitis A B vaccines for Hep C
    positive mothers

24
Urine Drug Testing (Toxicology)
  • If urine drug screening is required by protection
    services, it must be with maternal consent
  • If there has been maternal drug use, and there
    are medical concerns for the neonate and mother
    is unable or unwilling to give consent, then drug
    screens on neonate may be taken without consent
  • Note An unexpected positive result merits
    confirmatory testing! (same sample if possible)
  • (contd)

25
UDS - Toxicology
  • Voluntary urine testing
  • PROS agreement provides medical information for
    caregiver and suggests co-operation with medical
    care
  • Negative urine toxicology reports can show
    abstinence has been achieved and is helpful in
    interviews with child protection agencies
  • Valuable for monitoring treatment progress and
    enhancing motivation
  • Necessary in some centers if considering
    methadone maintenance therapy
  • CONS coercion can set up adversarial
    relationship between woman and care provider -
    open communication is critical component

26
Ongoing Care
  • Frequent visits
  • Consider pros and cons of multiple care providers
    (i.e., methadone prescriber and obstetrical
    provider should ideally be the same person or
    work in the same clinic)
  • Ongoing fetal health surveillance dependent on
    care provider

27
Strategies to Engage Women into Care
  • Reduce harm related to drug use - if abstinence
    is not achievable at present, focus on harm
    reduction
  • Focus on womans needs (woman-centered care
    food, housing, safety, emotional support)
  • Help women re-connect with the healthcare and
    social systems
  • Advocate on behalf of women with substance use
    issues with child protection authorities

28
Harm Reduction
  • When abstinence is not an option - consider harm
    reduction philosophies
  • Harm Reduction refers to any strategy that
    focuses on reducing the harmful consequences of
    drug use and associated high-risk behaviors
  • Example With some substances, abstinence is not
    a safe option during pregnancy methadone
    maintenance therapy is considered a harm
    reduction approach for opioid dependence in
    pregnancy

29
Management of Drug Use
  • Manage withdrawal symptoms
  • Consider pharmacological maintenance options,
    e.g., nicotine replacement therapy (NRT),
    methadone maintenance therapy (MMT) for opioid
    dependence
  • Encourage treatment program attendance if the
    patient is at a stage of change where she is
    ready for treatment
  • Discuss inpatient versus outpatient programs
  • Educate about fetal and maternal effects
  • Counsel about risks of Hepatitis BC, HIV

30
Management of Withdrawal
  • Drug withdrawal can potentially cause miscarriage
    in T1, premature labour in T3,adverse fetal
    effects including fetal distress
  • If a woman wishes to withdraw from Methadone or
    opiates, T2 (12-28 weeks GA) may be safest time
    for taper
  • The woman should be aware of her increased opiate
    needs during pregnancy, and risk of relapse with
    taper
  • Treatment is based on specific substance(s) used
    by woman so enquire about polydrug use (very
    common)
  • Medical detoxification recommended for opiates,
    benzodiazepines and alcohol

31
Management of Hepatitis C in Labour and Postpartum
  • Counsel all women about risk factors for
    hepatitis C and offer screening (repeat lab work
    if re-exposed)
  • If anti-HCV positive, monitor liver enzymes
  • Mode of delivery and breastfeeding have not been
    documented in transmission
  • Role of scalp clip in possible transmission may
    alter care patterns
  • Test babies with PCR at 3 to 6 months and if
    positive, repeat again at 18 months

32
Pain Management in Labour What can affect a
womans pain?
  • Hospital factors
  • Lack of support
  • Unwanted support
  • Loss of control
  • Hypervigilence
  • Lack of privacy
  • Harsh behaviour by staff
  • Personal factors
  • Past negative experience
  • Sexual abuse history
  • Fear, anxiety
  • Cultural perspective
  • Tolerance
  • Labour Occiput Posterior position
  • Previous pelvic fracture

33
Labour and Delivery Issues
  • Adequate analgesia opioid-dependent women may
    require larger doses of analgesics ? will not
    worsen addiction
  • Avoid a fetal scalp clip to prevent transmission
    of Hep B/C HIV
  • Injection drug users may have poor IV access ?
    planned IV access is recommended in case of
    emergency

34
Postpartum Issues
  • Rooming-in is the best option to encourage
    attachment and good parenting
  • Women may room in even if there is a planned
    removal of infant (to promote bonding and
    resilience)
  • If baby needs to go nursery, parents should
    accompany and be encouraged to hold and cuddle
    infant 24/7 if wanted
  • Encourage breastfeeding and regular visits with
    infant
  • Frequent f/u visits for mom baby to assess
    coping skills and neonatal growth
  • If UDS are medically needed, better to obtain
    consent from the mother

35
Postpartum Care
  • Ensure there are enough community supports in
    place before discharge to prevent relapse
  • Assess social support
  • Assist with basic needs (food, clothing, shelter)
  • Monitor for mood disorders
  • Link parents to community supports and parenting
    resources
  • Work with child protection as needed

36
Risks of Heavy Prenatal Alcohol Use
  • Alcohol passes through placenta fetus has
    limited ability to metabolize alcohol
  • Alcohol is a known teratogen ? can damage
    developing fetal cells, umbilical cord placenta
  • Prenatal exposure to alcohol results in
  • Increased risk of spontaneous abortion and
    stillbirth
  • Increased risk of fetal alcohol spectrum disorder
    (FASD) umbrella term encompassing fetal alcohol
    syndrome (FAS), alcohol-related birth defects and
    alcohol-related neurodevelopmental disorders

37
Safe Limits of Alcohol
  • Dose-response relationship between the amount of
    prenatal alcohol consumed and the extent of
    damage in the infant
  • There is NO safe timing for alcohol use during
    pregnancy
  • There is NO confirmed safe limit for alcohol use
    in pregnancy
  • Therefore, NO alcohol is the safest choice!

38
Social Alcohol Use Prior to Pregnancy
  • A meta-analysis failed to show any adverse fetal
    effects after social drinking (defined as greater
    than 2 drinks/week and up to and including 2
    drinks/day)
  • Moderate alcohol consumption before realizing
    that conception had occurred showed no increased
    risk of spontaneous abortion, stillbirth or
    premature birth
  • Women should be reassured and counseled to
    abstain for the duration of the pregnancy
  • Advise Folic Acid during pregnancy

39
Assisting if Low-Risk Alcohol Use
  • Brief interventions have been shown to be
    effective in modifying alcohol use during
    pregnancy
  • Consider the following for pregnant woman with
    history of low-risk drinking
  • Advise patient that it is safest to stop
    drinking.
  • Advise patient to reduce drinking, if unable to
    stop.
  • Advise by providing personalized feedback info.
  • Assist by providing continued follow-up support
    and referral to appropriate resources, as needed.

40
Assisting if High-Risk Use
  • If the pregnant woman indicates high-risk
    drinking
  • Assess level of motivation and readiness to
    change drinking behaviour severity of
    dependence
  • Offer intervention(s) depending on stage of
    change and level of alcohol dependence (e.g.,
    medical detoxification)
  • Advise her to reduce drinking, if unable to stop
  • Arrange referral to appropriate programs/services
  • Deal with barriers to attending treatment (e.g.,
    family)

41
Effects of Smoking in Pregnancy
  • Increased risk of spontaneous abortion
  • Increased risk of vaginal bleeding (placental
    abruption and placenta previa) and premature
    delivery
  • Increased risk of lower birth weight baby
    (150-200g less)
  • Increased risk of sudden infant death syndrome
    (SIDS), bronchitis pneumonia, otitis media in
    children

42
Smoking Cessation
  • Advise women to quit smoking
  • Advise woman to avoid exposure to second-hand
    smoke family/friends should not smoke around
    pregnant woman or infant, do not allow smoking in
    home or vehicle
  • Educate about effects of smoking in pregnancy
  • Refer to Smokers Helpline or Motherisk
  • Offer Nicotine Replacement Therapy (NRT)

43
Nicotine Replacement Therapy
  • Nicotine replacement therapy (NRT) poses no more
    adverse effects than smoking during pregnancy
  • Offer NRT if unable to quit on own
  • 1 pack/day 20mg nicotine (plasma level)
  • 1 Patch 7-21mg
  • Gum 2-4 mg/piece (max 12mg/day)
  • NRT doubles smoking cessation rates at 1 year

44
Marijuana
  • No studies have established safe limits in
    pregnancy
  • No significant neonatal effects
  • Heavy users may be at risk for preterm delivery
  • Possible neurobehavioural effects in neonate
    (increased jitteriness, increased tremors)
  • Possible long-term effects described in children
    exposed in utero
  • contd

45
Marijuana (2)
  • No specific therapy for withdrawal
  • Dependence managed by encouraging decrease in
    amount used if unable to abstain from marijuana
    use (harm reduction)
  • Marijuana is transferred into breast milk and
    abstinence is encouraged

46
Cocaine and Other Stimulants
  • Possibly teratogenic renal tract abnormalities
    (conflicting evidence in the literature)
  • Increased rate of obstetrical complications
  • Spontaneous abortion
  • Placental abruption, placenta previa
  • Premature rupture of membranes
  • Preterm labour
  • Low birth rate
  • Cerebral hemorrhage in utero
  • contd

47
Cocaine and Other Stimulants (2)
  • Can stop use safely during pregnancy
  • No specific therapy for withdrawal care is
    supportive
  • Can initially use short-acting benzodiazepines
    for anxiety and craving
  • contd

48
Cocaine and Other Stimulants (3)
  • If mother intoxicated at time of delivery neonate
    can have mild central nervous system effects
    such as poor feeding and sleepiness
  • Comfort Measures for neonate
  • Touch and cuddles by mother
  • Room-in with mother
  • Breastfeeding
  • contd

49
Cocaine and Other Stimulants (4)
  • Enters breast milk
  • Avoid breastfeeding within three days of use
    (pump and discard)
  • Long-term effects have been reported in
    literature (not definitive)
  • Language delays (expressive and verbal
    comprehension)
  • Behavioural problems at school

50
Opiates (1)
  • Women can take medically prescribed opiates in
    moderate doses during pregnancy without being
    considered dependent
  • Opioids can have a direct effect on fetal outcome
    with intrauterine growth restriction and
    low-birth weight especially heroin use and
    prescription opioid abuse
  • Women who are opioid-dependent also have higher
    rates of obstetrical complications spontaneous
    abortion, preterm labour in T3 and fetal distress
  • contd

51
Opiates (2)
  • Standard of care for opioid dependence in
    pregnancy- Methadone Maintenance Therapy (MMT)
  • Methadone maintained pregnancies have improved
    outcomes
  • Methadone dose should be maintained during labour
  • Some women will need a reduction in methadone
    dose postpartum
  • contd

52
Opiates (3)
  • Maternal Withdrawal
  • If not on methadone, can use morphine for the
    management of withdrawal
  • Neonatal Withdrawal
  • Some babies of women on opiates will experience
    neonatal withdrawal
  • Comfort measures
  • Some babies will need replacement opiates
  • Oral Morphine can be used in small doses to
    manage symptoms
  • contd

53
Opiates (4)
  • Methadone enters breast milk
  • Safe to breastfeed on methadone regardless of
    dose
  • Neonates should be observed at least 4-5 days for
    signs of withdrawal
  • Ensure close follow-up of mother and baby

54
Conclusion
  • Woman-centered, nonjudgmental care needed
  • Know the substances commonly used in your
    community
  • Treat substance use when woman is ready for
    treatment
  • Consider Harm Reduction if abstinence is not
    possible initially

55
Resources (1)
  • Pregnancy-related issues the management of
    addictions (PRIMA) www.addictionpregnancy.ca
  • Best Start www.beststart.org
  • PREGNETS www.pregnets.org
  • Smokers Helpline Ontario 1-877-513-5333
  • Project CREATE www.addictionmedicine.ca
  • Motherisk www.motherisk.org

56
Resources (2)
  • BC Doctors Stop Smoking Program www.bcdssp.com
  • BC HealthFile info Sheet. http//www.bchealthguid
    e.org/healthfiles/hfile38d.stm
  • Babies Best chance Handbook http//www.healthserv
    ices.gov.bc.ca/cpa/pulications/babybestchance.pdf
  • Is it Safe for my Baby? Booklet CAMH
    www.camh.net
  • Info sheets, posters AADAC www.aadac.com
  • AADAC Help Guide for Professionals www.aadac.com
  • BCRCP Guidelines www.rcp.gov.bc.ca
  • Smart Guide
  • Exposure to Psychotropic Medications and Other
    Substances During Pregnancy and Breastfeeding A
    Handbook for Health Care Providers. Free from
    CAMH. www.camh.net

57
Pregnancy-Related Issues in the Management of
AddictionsSlide presentation developed by
members of the National PRIMA group
  • Ron Abrahams
  • Talar Boyajian
  • Jennifer Boyd
  • Wendy Burgoyne
  • Katherine Cardinal
  • Rosa Dragonetti
  • Lisa Graves
  • Phil Hall
  • Samuel Harper
  • Georgia Hunt
  • Meldon Kahan
  • Theresa Kim
  • Lisa Lefebvre
  • Nick Leyland
  • Margaret Leslie
  • Deana Midmer
  • Stephanie Minorgan
  • Pat Mousmanis
  • Alice Ordean
  • Sarah Payne
  • Peter Selby
  • Melanie Smith
  • Ron Wilson
  • Suzanne Wong

Principal Authors
Prima.medicine_at_utoronto.ca
Write a Comment
User Comments (0)
About PowerShow.com